0
Skip to Content
Nordic Migraine Symposium 2026
Home
Agenda
Venue & Accommodation
NMS 2025
NMS 2024
NMS 2023
NMS 2022
NMS 2021
NMS 2020
NMS 2019
Contact
REGISTER NOW
Nordic Migraine Symposium 2026
Home
Agenda
Venue & Accommodation
NMS 2025
NMS 2024
NMS 2023
NMS 2022
NMS 2021
NMS 2020
NMS 2019
Contact
REGISTER NOW
Home
Agenda
Venue & Accommodation
Folder: Previous years
Back
NMS 2025
NMS 2024
NMS 2023
NMS 2022
NMS 2021
NMS 2020
NMS 2019
Contact
REGISTER NOW

Comorbidities and management

Session 4: Difficult to treat patients

Gürdal Sahin

MD, PHD

Previous

New EHF guideline on the use of MAb’s for migraine prevention

Next

Combining preventative therapies

You Might Also Like

Related Embedded Video Item Thumbnail Misconceptions on migraine and treatments - social media, Google, etc.
Related Embedded Video Item Thumbnail Biomarkers with focus on genetics
Related Embedded Video Item Thumbnail Treatment response as a biomarker
Related Embedded Video Item Thumbnail Migraine in pediatric
Related Embedded Video Item Thumbnail Patient FAQs & demands and how to address

Privacy policy

Teva Privacy Notice |Teva Pharmaceuticals

Legal Notes | Teva Pharmaceuticals

Accessibility Statement

Teva code of conduct


Norway, Finland, Denmark: AJO-DK-NP-00128